

Myocardial Biology Laboratory University Hospital, Cardiology University of Bern Switzerland

IJ,

b UNIVERSITÄT BERN

### Human iPSC-derived cardiomyocytes: A comparison with primary cells and applications in standard and 3D culture models

Dr. sc. nat. Christian Zuppinger

Bern University Hospital, Cardiology Department

#### studying cardiomyocyte biology in vitro



# Sources of primary cardiomyocytes and isolation methods





Neonatal mouse or rat



Explanted and perfused animal heart



Human atrial appendage









# Primary cardiomyocytes in culture: a challenging cell type

- Terminally differentiated: <u>no proliferation</u>, limited life time in culture (2 days or approx. 2 weeks in dedifferentiated longterm culture with serum)
- Almost <u>no immortalized cell lines</u> available (few existing, from animal origin and with little advantages compared to neonatal rodent primary cells)
- Cardiac muscle is depending on uninterrupted <u>oxygen supply</u>, therefore living human organs are rare and mostly used for transplantation, valve surgery etc.

### The need for better *in vitro* models

We need:

- Cardiomyocytes from <u>human</u> origin for taking into account speciesspecific signaling pathways, genetic mechanisms, (electro-)physiological differences and for testing antibody-therapies
- A constant quality of cells in each lot
- A cellular environment involving mechanical and paracrine (co-culture) stimuli



➔ 3D culture of scaffold-free microtissues aggregated in the hanging drop with/without other cardiovascular cell types

# Production of induced pluripotent stem cells (iPSC)-derived cardiomyocytes from human origin and potential applications



#### **iPSC-Derived Ventricular Cardiomyocytes** Safety pharmacology testing

#### **Untreated Action Potential Parameters**





#### **Compounds Tested**

Compound	Ion channel	
Nifedipine	I <sub>Cav</sub>	
TTX, Mexiletine and Lidocaine	I <sub>Nav</sub>	
Verapamil	I <sub>Cav</sub> & I <sub>Kr</sub>	
Dofetilide	I <sub>Kr</sub>	
Carbachol	I <sub>KACh</sub>	
4-Aminopyridine (4-AP)	Non-selective K <sub>v</sub> channel blocker	
Tertiapin- Q	Selective Kir3.1/3.4 blocker	







 $\mathsf{Nifedipine}\;(\mathsf{I}_\mathsf{Cav})$ 



APDOO





Dofetilide (I<sub>Kr</sub>)

APD20

APD50

- Consistent and reliable results (n=32),
- Resting membrane potential -75 mV to -80 mV
- Broad action potential duration (APD90>300 ms)
- Relevant ion channel expression of  $I_{Nav'}$   $I_{Cav}$  and  $I_{Kr}$

Additional techniques for drug evaluation with cultured hiPSC cardiomyocytes



Data provided by Matthew Daniels' Group at Oxford University, Jason Gill at Durham University

## What is the developmental stage of hiPSC-Cardiomyocytes?

Organization of cytoskeleton and sarcomeric proteins in comparison to adult ventricular cardiomyocytes



#### myomesin actin

#### myomesin vimentin

MLC2a MLC2v

#### Telethonin (t-cap) all actin



#### Cardiac ankyrin repeat protein (CARP) all actin



#### Comparison with fully differentiated cardiomyocytes from adult rats



#### Bridging the gap between cell culture and the patient





### **3D cell culture for cardiac cells?**





Illustration from "3D culture for cardiac cells". Zuppinger C. Biochim Biophys Acta. Vol 1863(7), 2015





perfused rat heart freshly isolated rat CM (paced) spontaneously contracting long-term cultured rat CM



From: Springer Protocols, 2017, "Stem cell-derived models in toxicology", Zuppinger, C., "Edge-Detection for Contractility Measurements with Cardiac Spheroids"

# Is the proposed difference between standard culture and 3D models - or superiority of 3D culture - a claim supported by actual data ?

# Spheroid tumor models: strinking differences between 2D and 3D regarding chemotherapy efficacy

IC50 [µM]	Cisplatin	Doxorubicin	Etoposide	Vinblastine
Monolayer	$3.0 \pm 0.5$	$0.2 \pm 0.1$	$3.2 \pm 0.3$	$0.008 \pm 0.001$
Spheroids	81 ± 15	7 <u>+</u> 1	521 <u>+</u> 80	53 <u>+</u> 6
3D model: orbit	al agitation	A549 lung ca	rcinoma cell line	
Resistance d • R • R • D • H	ue to: educed uptake esistance to ap offerences in p lypoxic and ne	e ooptosis roliferation profi crotic center	le	
B. Desoize Crit Rev Onco Nederman T, Carlsson J. Slide: InSphero	ol Hematol. 2000 Nov-De . Cancer Chemother Pha	c;36(2-3):193-207. rmacol 1984;13:131–5.		

20

# For controlled <u>co-culture</u> of different cardiac cell types: 3D-culture is the way to go

•Approximation to original tissue structure

•To avoid inclusion of animal proteins (naturally forming extracellular matrix)

•Functionality of artificial tissues is improved

•Drug actions on paracrine pathways and inter-cellular mechanisms (for example fibrosis, myocarditis) can be tested in co-culture

### Outlook

- iPSC-derived cell models have come of age, can be used for drug development and disease modeling
- Improved maturation of iPSC-derived cardiomyocytes is preferred and currently in development
- More sophisticated 3D models will be used including multiple cell types, in situ sensors/imaging, miniaturization of incubators (organ on chip)
- Bioprinting and self-assembly strategies for artificial organs





insphero Biomimetic Microtissue Technology

> <u>InSphero</u> Jens Kelm Irina Agarkova



<u>Axolbioscience</u> Priyanka Dutta-Passecker George Gibbons

Cardiology Department

O. Hess, B. Meier

Thomas M. Suter

Dept. Clinical Research Hugues Abriel

& Group

#### Financial support:

Federal Commission for Technology and Innovation (CTI/KTI)

**Swiss Heart Foundation** 

 $u^{\scriptscriptstyle b}$ 

b UNIVERSITÄT BERN

<u>Physiology Inst.</u> Nina Ullrich